0 CHECKOUT

IL-1 Signaling Pathway in Oncology Drug Pipeline Update

  • ID: 1537329
  • August 2016
  • Region: Global
  • Bioseeker
1 of 2

The IL-1 signaling pathway activates the MAPK/JNK signaling modules. The MAPK pathway leads to activation of NFkB complex. As both IL-1 and TNF alpha stimulate the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity.

There are today 111 companies plus partners developing 113 IL-1 pathway targeting drugs in 415 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 55 drugs. Il-1 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 96 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 95 out of the 95 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 28 classifications of molecular function and with READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)